Inflammatory Properties and Adjuvant Potential of Synthetic Glycolipids Homologous to Mycolate Esters of the Cell Wall of Mycobacterium tuberculosis

Hermann Giresse Timar, Juma’a Raheem Al Dulayymi, Olivier Denis, Pauline Lehebel, Klarah Sherzad Baols, Mohsin Omar Mohammed, Laurent L’Homme, Mohamed Mohammed Sahb, Georges Potemberg, Sylvie Legrand, Roland Lang, Rudi Beyaert, Jacques Piette, Mark Stephen Baird, Kris Huygen, Marta Romano

Abstract

The cell wall of mycobacteria is characterised by glycolipids composed of different classes of mycolic acids (MAs; alpha-, keto-, and methoxy-) and sugars (trehalose, glucose, and arabinose). Studies using mutant Mtb strains have shown that the structure of MAs influences the inflammatory potential of these glycolipids. As mutant Mtb strains possess a complex mixture of glycolipids, we analysed the inflammatory potential of single classes of mycolate esters of the Mtb cell wall using 38 different synthetic analogues. Our results show that synthetic trehalose dimycolate (TDM) and trehalose, glucose, and arabinose monomycolates (TMM, GMM, and AraMM) activate bone marrow-derived dendritic cells in terms of the production of pro-inflammatory cytokines (IL-6 and TNF-α) and reactive oxygen species, upregulation of co-stimulatory molecules, and activation of NLRP3 inflammasome by a mechanism dependent on Mincle. These findings demonstrate that Mincle receptor can also recognise pentose esters and seem to contradict the hypothesis that production of GMM is an escape mechanism used by pathogenic mycobacteria to avoid recognition by the innate immune system. Finally, our experiments indicate that TMM and GMM, as well as TDM, can promote Th1 and Th17 responses in mice in an OVA immunisation model, and that further analysis of their potential as novel adjuvants for subunit vaccines is warranted.

Keywords

Mycobacterium tuberculosis · Glycolipids · Trehalose dimycolate · Trehalose monomycolate · Glucose monomycolate · Arabinose monomycolate · Inflammasome · Adjuvant

Dr. Marta Romano
Scientific Service Immunology, O.D. Communicable and Infectious Diseases
Scientific Institute of Public Health (WIV-ISP), 642 Rue Engelandstraat
BE–1180 Brussels (Belgium)
E-Mail mart.a.romano@wiv-isp.be

M.S.B, K.H., and M.R. share senior authorship.
**Introduction**

*Mycobacterium tuberculosis* (*Mtb*), the causative agent of tuberculosis, belongs to the single genus *Mycobacterium* of the Mycobacteriaceae family. Bacteria from this family are characterised by the presence in their cell wall of high molecular weight C-60 to C-90 2-alkyl-3-hydroxy fatty acids called mycolic acids (MAs). MAs are the major lipids constituting the mycobacterial cell wall fatty acids called mycolic acids (MAs). MAs are the major of high molecular weight C-60 to C-90 2-alkyl-3-hydroxy family are characterised by the presence in their cell wall um as free MAs [3] or esterified to different sugars. They are predominantly bound to the cell wall with arabinogalactan as penta-arabinose tetramycolates, but they are also present as non-bound solvent extractable esters, such as trehalose mono- and dimycolate (TMM and TDM), glucose monomycolate (GMM) and glycerol monomycolate [1, 2].

Among these components, trehalose 6,6'-dimycolate (TDM) – also known as cord factor – is the major and most studied mycolate ester. Indeed, in mouse models TDM can mimic certain aspects related to *Mtb* infection, including the production of pro-inflammatory cytokines [4, 5], the induction of granuloma and procoagulant activity [6–8]. In addition, TDM can delay phagolysosome fusion [9], is involved in tissue damage and necrosis, and possesses adjuvant properties [10]. However, the natural TDM used in these different studies was isolated from mycobacteria and consisted of a complex mixture of structurally related compounds composed of mycolates from different classes. Indeed, based on the functional group(s) present on their meromycolate chain, MAs are subdivided in different classes. The principal classes are the alpha-, keto-, and methoxy-MAs. These classes differ considerably between mycobacterial species and strains [11], and appear to influence their virulence. For example, the attenuated vaccine strain *M. bovis* BCG-Pasteur lacks methoxy-MAs [12] and saprophytic mycobacteria such as *M. smegmatidis* fail to produce oxygenated (keto- and methoxy-) MAs [2]. In contrast, highly pathogenic mycobacteria such as *Mtb* and *M. leprae* produce oxygenated MAs. Genetic inactivation of enzymatic pathways involved in the synthesis of oxygenated MAs resulted in in vivo-attenuated *Mtb* strains [13, 14]. Therefore, the use of synthetic analogues can be useful to discriminate the contribution of different types of TDM or of mycolate esters in general to the pathogenicity of mycobacterial infection and to the inflammatory potential of these cell wall components. Indeed, the contribution of other mycolate esters found in the cell wall of *Mtb* such as TMM, GMM, and arabinose mycolates (AraMMs) in the activation of innate immune cells following mycobacterial infection is poorly defined.

TMM is known as a key precursor for the biosynthesis of TDM and has been reported to have some similarity with TDM in terms of inflammatory potential [4, 15, 16]. GMM has been demonstrated to be an antigen that is presented by CD1b molecules to T cells [17], but the activation of innate immune cells by GMM from *Mtb* is controversial. Indeed, it was reported that Mincle (macrophage inducible C-type lectin receptor) does not recognise GMM obtained by trehalase treatment of TDM [18], but that GMM of corynebacteria (C-32 mycolates in corynebacteria vs. C-60 to C-90 mycolates in mycobacteria) binds to Mincle and activates cells [19]. Mincle and MCL (macrophage C-type lectin) have been shown to be essential receptors for the recognition of TDM [18, 20] and TMM [21], and hence crucial for the stimulation of cord factor-induced innate immune responses. On the other hand, the arabino-mycolate ester (a complex mixture of mono-AraMMs, tetra-arabinose tetra-mycolates, penta-arabinose tetra-mycolates, and hexa-arabinose tetra-mycolates) obtained by acid hydrolysis of the BCG cell wall skeleton was reported to induce the production of TNF-α by mechanisms dependent on the TLR-2/MyD88 pathway [22]. Finally, it has been shown that trehalose dihexa (TDB), a short-acyl-chain structural analogue of TDM, activates the intracellular multiprotein complex called the NLRP3 inflammasome [23] and that this activation is essential for the Th17 responses induced by TDB [24]. For the moment, it is still unknown whether TMM, GMM, and arabinose mycolates can activate the inflammasome as well.

To address the relationship between the structure and the inflammatory power of mycolate esters and the signalling pathways involved, in this study we assayed 38 single synthetic mycolate ester isomers of high purity and known stereochemistry [25–28]. The mycolate esters tested here vary in terms of their carbohydrate moiety (trehalose, glucose, or arabinose) and in terms of the number, nature, and class of MAs bound to it. The selected mycolate esters are composed of MAs that are representative of the major classes found in the cell wall of *Mtb*, namely alpha-, methoxy-, and keto-mycolates of either the cis or trans configuration and with different chain lengths. In addition, synthetic mycolate esters composed of alpha-mycolates containing an alkene group and homologous to those found in non-pathogenic mycobacteria (such as *M. smegmatis*) were also tested here for comparison purposes. Using murine bone marrow-derived dendritic cells (BMDCs), we examined in vitro the ability
of these compounds to induce the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-12, and IL-1β) and we identified the pathways involved in their inflammatory potential. We also confirmed their in vivo inflammatory potential and tested their adjuvant capacity to promote adaptive immune responses in an ovalbumin vaccination model.

**Material and Methods**

**Mice**

C57BL/6mecf, MyD88−/−, and MALT1−/− mice were bred and kept at the experimental animal facilities of WIV-ISP (Ukkel site, Brussels), complying with the Belgian legislation that transposes European Directive 2009/41/EC, repealing Directive 90/219/EC (EC, 2009). For some experiments, female C57BL/6 mice aged 6–8 weeks were purchased from Janvier Labs. Breeding pairs of MyD88−/− mice were kindly provided by C. Desmet (Cellular and Molecular Physiology, GIGA-Research, ULeu, Belgium). MALT1−/− mice were as described [29]. Bones (femurs and tibia) of Mincle−/−, FcRγ−/−, and NLRP3−/− mice were provided by R. Lang (University Clinics Erlangen, Germany) and B. Ryffel (CNRS, Orleans, France).

**Preparation of Glycolipid-Coated Plates**

Stocks of synthetic glycolipids (synthesised at Bangor University) [25–28, 30, 31], TDB (Invivogen), and natural TDM from Mtb (Adipogen) were solubilised in chloroform-methanol solution (9:1) at 5 mg/mL. The different glycolipids were then dissolved in isopropanol (ISO) and coated on flat-bottomed culture plates (Greiner). After evaporation of the solvent, the plates were used directly or stored at −20°C. The final concentrations are indicated in the figure legends and Results section. For the experiments performed at equimolar concentrations, the molarity of natural TDM (a mix) was calculated using an estimated molecular weight of 2,754 g/mol. A possible negative effect of the tested glycolipids on cell viability was tested by Alamar blue assay and no increased mortality was observed under the test conditions.

**Generation of BMDCs**

BMDCs were generated as previously described [32]. Briefly, murine bone marrow from the femur and tibia was flushed with PBS and red blood cells were lysed with Sigma’s lysing buffer. After lysis, cells were cultured (5% CO2 at 37°C) in a T75 flask in RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) supplemented with 10 ng/mL recombinant murine GM-CSF (ImmunoTools), 5 × 10−5 M 2-mercaptoethanol, 100 μg/mL gentamycin (GIBCO), 2 mM glutamine, 1 mM sodium pyruvate, non-essential amino acids (Thermo Fisher Scientific), and 10% foetal calf serum (FCS; Greiner). Cells were differentiated for 6–7 days and the medium was replaced every 3 days. Ninety per cent of CD11c-positive cells were obtained after differentiation.

**In vitro Stimulation with Glycolipids and Analysis of Samples**

BMDCs were harvested after 7 days using a cell scraper, counted and seeded in glycolipid-coated plates at a concentration of 106 cells/mL for different time periods. Culture supernatants were collected after 24 h and the content of pro-inflammatory cytokines TNF-α, IL-12p40, IL-1β, and IL-6 was determined by ELISA (eBiosciences).

The expression of costimulatory molecules was analysed after 48 h of incubation with the different compounds. Cells were labelled with anti-mouse CD80, anti-mouse CD86, and anti-mouse major histocompatibility complex class II (MHC-II) monoclonal antibodies (eBiosciences). Fluorescence was analysed using a FACSCalibur flow cytometer and CELL-QUEST software (BD Biosciences).

**HEK-Blue mMincle Stimulation**

HEK (human embryonic kidney)-blue mMincle cells (Invivogen) stably transfected with murine C-type lectin receptor mincle gene, as well as the genes of the Mincle-NF-κB signalling pathway and secreted embryonic alkaline phosphatase (SEAP) under the control of NF-κB activation, were used to analyse the activation of the Mincle receptor by the compounds. HEK-blue mMincle cells were cultured in Dulbecco’s modified Eagle’s medium containing 4.5 g/L glucose and supplemented with 10% FCS, selective antibiotics, and 2 mM glutamine. Cells were passed in a T75 flask when 70–80% confluence was reached. For the stimulation, cells were seeded in 96-well plates at a density of 5 × 104 cells/well for 24 h. Quanti-blue substrate (Invivogen) was used for the detection of SEAP in the supernatant according to the manufacturer’s instructions.

**Inflammasome Assays**

BMDCs at 1 × 106 cells/mL were primed for 3 h with 1 μg/mL of *Escherichia coli* K12 ultra-pure LPS (Invivogen) prior to stimulation with glycolipids (on coated plates) and controls. Cells were stimulated in triplicate with 5 mM ATP (for 1 h) or 10 μg/mL of MA esters (for 5 h). For the inhibition studies, glibenclamide (50 μM; Sigma), ebselen (10 μM; Sigma), cytochalasin D (1 μM; Sigma), CA-074 methyl ester (10 μM; Sigma), and Z-VAD-FMK (10 μM; Invivogen) were added 1 h prior to glycolipid stimulation. The effect of these inhibitors on cell viability was tested by Alamar blue or MTT assay and no increased mortality was observed under the test conditions. IL-1β cytokine production in cell-free supernatant was evaluated by ELISA (eBiosciences).

For the detection of activated caspase-1 in supernatants, cells were stimulated in FCS-free medium. Triplicate samples were pooled and the proteins were concentrated by methanol-chloroform precipitation. Briefly, 500 μL of supernatant was mixed with 500 μL of methanol and 125 μL of chloroform, vortexed and centrifuged. The aqueous phase was collected, washed with methanol, mixed and centrifuged. The supernatant was discarded and the pellet was dried, reconstituted in SDS sample buffer (75 mM Tris-HCl, pH 6.8, 100 mM DTT, 2% SDS, 0.01% bromophenol blue and 10% glycerol) and heated for 5 min at 95°C. Proteins were separated by electrophoresis for 1.5 h at 100 V in 15% Tris-Glycine Gel and transferred to a nitrocellulose membrane using a semi-dry system (Amersham Bioscience). Three per cent BSA and TBS-Tween 20 were used as blocking and washing buffer, respectively. Monoclonal mouse anti-caspase-1 p20 Casper-1 (Adipogen) was used as the primary antibody and polyclonal goat anti-mouse IgG HRP (R&D Systems) as a secondary antibody. The revelation was done by applying ECL substrate (GE Healthcare Life Sciences) on the membrane and pictures were taken using an ImageQuant LAS 4000 device.
Analysis of Adaptive Immune Responses

One week after the administration of the w/o/w samples, mice were sacrificed, and the tissues of the hind footpads were collected and strained with a 100-μm nylon cell strainer (BD Biosciences). Cells were collected and digested using collagenase and DNase (Sigma). Cells were collected and stained with a 100-μm nylon cell strainer (BD Biosciences). Total RNA was isolated from footpad cells with Trizol reagent (Sigma-Aldrich) according to the manufacturer’s instruction. cDNA was prepared using the GoScript Reverse Transcriptase system (Promega). qRT-PCR was performed on Stratagene Mx3000p using the GoTaq qPCR Master mix (Promega) according to the manufacturer’s instructions. The forward and reverse primers used are described below. GAPDH was used as the reference housekeeping gene for the normalisation. Additionally, footpad cells were incubated with Ly6G-Ly6C PE and viability dye V450 (eBiosciences), and the fluorescence was analysed with a FACS Calibur flow cytometer and CELL QUEST software (BD Biosciences).

Footpad Immunisation with Ovalbumin

Water in oil in water (w/o/w) emulsions were prepared by minor modification of a previously described protocol [33]. Briefly, glycolipids were dissolved in 30% incomplete Freund’s adjuvant (IFA) and vortexed vigorously. Next, 0.1 mL PBS was added and vortexed again vigorously to make a water in oil emulsion, and finally PBS containing 0.2% of Tween 80 and the required amount of ovalbumin was added to the water in oil preparation to make a w/o/w emulsion. Groups of 4–5 mice were injected subcutaneously in both hind footpads with 25 μL of the emulsion containing 30% IFA, 5 μg of glycolipids, and 25 μg of ovalbumin (Invivogen). Footpad swelling in individual mice was measured with a caliper before and at several time points after injection.

Analysis of Local Footpad Inflammation

One week after the administration of the w/o/w samples, the mice were sacrificed and the tissues of the hind footpads were collected and digested using collagenase and DNase (Sigma). Cells were collected and strained with a 100-μm nylon cell strainer (BD Biosciences). Total RNA was isolated from footpad cells with Trizol reagent (Sigma-Aldrich) according to the manufacturer’s instruction. cDNA was prepared using the GoScript Reverse Transcriptase system (Promega). qRT-PCR was performed on Stratagene Mx3000p using the GoTaq qPCR Master mix (Promega) according to the manufacturer’s instructions. The forward and reverse primers used are described below. GAPDH was used as the reference housekeeping gene for the normalisation. Additionally, footpad cells were incubated with Ly6G-Ly6C PE and viability dye V450 (eBiosciences), and the fluorescence was analysed with a FACS Calibur flow cytometer and CELL QUEST software (BD Biosciences).

Primers

CXCL1 forward: 5′-CCGAAGTCTAGCCACACTCAA-3′; CXCL1 reverse: 5′-GCAGTCTCTTCTTCTCCGTATC-3′; IL-1β forward: 5′-TTGACGGACCCCCAGAT-3′; IL-1β reverse: 5′-AGCTGGATGCTCTGATCGG-3′; IL-12p35 forward: 5′-CCTCGGCATCCAGC-3′; TNC-a forward: 5′-CATCTTCATCAATTCTGAGTGAC-3′; TNC-a reverse: 5′-GGAGTAGACAGGTCACACCC-3′; GAPDH forward: 5′-TCGGGCTTGTGACTGTCGGTT-3′; GAPDH reverse: 5′-TCCCAGCGCTGTCGTCGAC-3′.

Analysis of Adaptive Immune Responses

One week after the administration of the different w/o/w preparations, mice were sacrificed, popliteal and inguinal lymph nodes were removed and passed through a 100-μm nylon cell strainer (BD Biosciences). Cells were counted and stimulated in RPMI medium supplemented with 5 × 10^{-5} M 2-mercaptoethanol, antibiotics, and 10% FCS in round-bottomed 96-well plates with 5 μg/mL of ovalbumin, culture medium as a negative control and Concavalin A (4 μg/mL, Sigma) as a positive control. Cell-free culture supernatants were harvested after 24 and 72 h of incubation at 37°C, 5% CO₂. Levels of IL-2 were measured in 24-h supernatants by ELISA (eBiosciences). Levels of IFN-γ and IL-17A were determined in 72-h supernatants by ELISA (BD Pharmingen and eBiosciences, respectively).

Statistical Analyses

Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, La Jolla, CA, USA). For the statistical analysis of the in vitro experiments, data from 3–4 independent experiments were pooled and tested for a Gaussian distribution with the D’Agostino Pearson test followed by pairwise comparisons performed by the Mann-Whitney test. For the analysis of the in vivo experiments, pairwise comparisons were performed by Mann-Whitney test. For all analyses, p < 0.05 was considered statistically significant.

Results

Synthetic TDMs and TMMs Are Inflammatory

To study the influence of the class of mycolates and the number of mycolate chains on the inflammatory potential of trehalose mycolate esters, 17 TDMs and 13 TMMs were synthesised (Table 1, TDM and TMM columns) [25–28, 30, 31]. These compounds vary in terms of their MA class (alpha-, methoxy-, keto-), the configuration of their cyclopropanation (cis- vs. trans-), and the number of MAS bound to trehalose (dimycolates vs. monomycolates). BMDCs were incubated for 24 h with the different synthetic TMMs, TDMs, evaporated ISO as a negative control, trehalose-6,6-dibehenate (TDB), or TDM isolated from Mtb (TDM natural mix) as positive controls. The production of the pro-inflammatory cytokines IL-6 and TNF-a was evaluated by ELISA in culture supernatants and the results obtained for 10 TDMs and 9 TMMs at equimolar concentrations are shown in Figure 1, while results obtained at 10 μg/mL for 16 TDMs and 11 TMMs are shown in online supplementary Table S1 (see www.karger.com/doi/10.1159/000450955 for all online suppl. material). All the tested synthetic TMMs and TDMs stimulated the production of TNF-a and IL-6. Interestingly, when dose-response analysis was performed with pairs of TMMs and TDMs composed of the same mycolic moiety, we observed that the number of mycolate chains bound to trehalose influenced the level of TNF-a and IL-6 produced. Indeed, as shown in Figure 1a and b, at equimolar concentrations the cis-methoxy TMM KB51 (monomycolate) induced TNF-a and IL-6 levels that were 2- to 3-fold lower than those achieved by stimulation with the corresponding cis-methoxy TDM KB52 (dimycolate).
| Class of mycolic acid | Structure of mycolic acid | TDM | TMM | GMM | AraMM |
|-----------------------|---------------------------|-----|-----|-----|-------|
| Alpha mycolic acids   |                           |     |     |     |
| α                    | [CH₃(CH₂)₁₉]               |     |     |     |
|                      | [CH₂]₁₄                   |     |     |     |
|                      | [CH₃(CH₂)₁₄]              |     |     |     |
|                      | [CH₂]₁₇                   |     |     |     |
|                      | [CH₃(CH₂)₁₇]              |     |     |     |
|                      | [CH₂]₂₁                  |     |     |     |
|                      | [CH₃(CH₂)₂₁]             |     |     |     |
| α                    | [CH₃(CH₂)₁₉]               |     |     |     |
|                      | [CH₂]₁₄                   |     |     |     |
|                      | [CH₃(CH₂)₁₄]              |     |     |     |
|                      | [CH₂]₁₇                   |     |     |     |
|                      | [CH₃(CH₂)₁₇]              |     |     |     |
|                      | [CH₂]₂₁                  |     |     |     |
|                      | [CH₃(CH₂)₂₁]             |     |     |     |
| α                    | [CH₃(CH₂)₁₉]               |     |     |     |
|                      | [CH₂]₁₄                   |     |     |     |
|                      | [CH₃(CH₂)₁₄]              |     |     |     |
|                      | [CH₂]₁₇                   |     |     |     |
|                      | [CH₃(CH₂)₁₇]              |     |     |     |
|                      | [CH₂]₂₁                  |     |     |     |
|                      | [CH₃(CH₂)₂₁]             |     |     |     |
| α                    | [CH₃(CH₂)₁₉]               |     |     |     |
|                      | [CH₂]₁₄                   |     |     |     |
|                      | [CH₃(CH₂)₁₄]              |     |     |     |
|                      | [CH₂]₁₇                   |     |     |     |
|                      | [CH₃(CH₂)₁₇]              |     |     |     |
|                      | [CH₂]₂₁                  |     |     |     |
|                      | [CH₃(CH₂)₂₁]             |     |     |     |
| α                    | [CH₃(CH₂)₁₉]               |     |     |     |
|                      | [CH₂]₁₄                   |     |     |     |
|                      | [CH₃(CH₂)₁₄]              |     |     |     |
|                      | [CH₂]₁₇                   |     |     |     |
|                      | [CH₃(CH₂)₁₇]              |     |     |     |
|                      | [CH₂]₂₁                  |     |     |     |
|                      | [CH₃(CH₂)₂₁]             |     |     |     |
| α                    | [CH₃(CH₂)₁₉]               |     |     |     |
|                      | [CH₂]₁₄                   |     |     |     |
|                      | [CH₃(CH₂)₁₄]              |     |     |     |
|                      | [CH₂]₁₇                   |     |     |     |
|                      | [CH₃(CH₂)₁₇]              |     |     |     |
|                      | [CH₂]₂₁                  |     |     |     |
|                      | [CH₃(CH₂)₂₁]             |     |     |     |
| α                    | [CH₃(CH₂)₁₉]               |     |     |     |
|                      | [CH₂]₁₄                   |     |     |     |
|                      | [CH₃(CH₂)₁₄]              |     |     |     |
|                      | [CH₂]₁₇                   |     |     |     |
|                      | [CH₃(CH₂)₁₇]              |     |     |     |
|                      | [CH₂]₂₁                  |     |     |     |
|                      | [CH₃(CH₂)₂₁]             |     |     |     |
| α                    | [CH₃(CH₂)₁₉]               |     |     |     |
|                      | [CH₂]₁₄                   |     |     |     |
|                      | [CH₃(CH₂)₁₄]              |     |     |     |
|                      | [CH₂]₁₇                   |     |     |     |
|                      | [CH₃(CH₂)₁₇]              |     |     |     |
|                      | [CH₂]₂₁                  |     |     |     |
|                      | [CH₃(CH₂)₂₁]             |     |     |     |
| α                    | [CH₃(CH₂)₁₉]               |     |     |     |
|                      | [CH₂]₁₄                   |     |     |     |
|                      | [CH₃(CH₂)₁₄]              |     |     |     |
|                      | [CH₂]₁₇                   |     |     |     |
|                      | [CH₃(CH₂)₁₇]              |     |     |     |
|                      | [CH₂]₂₁                  |     |     |     |
|                      | [CH₃(CH₂)₂₁]             |     |     |     |

Keto mycolic acids

| cis-keto | AD132 [27] | AD134 [27] |
|----------|------------|------------|
| trans-keto | RT136 [27] |            |
| cis-keto | RT137 [31] |            |
| trans-keto | RT82 [31] | RT86 [31] |
TNF-α levels induced by KB51 were comparable to those induced by TDB, while IL-6 levels induced by KB51 were lower than those obtained by TDB. This influence of the number of mycolate chains on the intensity of the inflammatory response was observed for a total of 9 TMM/TDM pairs representative of the different classes and configurations of mycolates present in mycobacteria (Fig. 1c). Indeed, statistically significant differences in the levels of TNF-α (Fig. 1c) and IL-6 (data not shown) were observed when comparing the data obtained for a given TDM with
the data obtained for the corresponding TMM (same mycolate moiety). In addition, the majority of the tested TDM compounds induced significantly more TNF-α compared to TDB (statistical analysis not shown). Only the dialkene TDM (ST198) and the cis-keto TDM (AD132) induced TNF-α levels comparable to those induced by TDB (Fig. 1c). Concerning the influence of the class of MAs on the levels of inflammatory responses induced by
TDM, 8 synthetic TDMs representative of the different classes and configurations of mycolates present in mycobacteria were selected and a dose-response analysis was performed. All the tested synthetic compounds induced significant TNF-α production already at the lowest 0.001 μM concentration tested and a response plateau was observed at 0.1–1 μM (online suppl. Fig. S1). To compare the responses induced with TDMs from the same class but of different configurations (cis- vs. trans-), data obtained in 3 independent experiments at 1 μM with alpha, keto, or methoxy TDMs of cis- or trans-configuration were pooled and the differences were analysed statistically (Fig. 1d). Results indicated that the tested trans-alpha TDM (MMS139) was more inflammatory than the tested cis-alpha TDM (MH175), while for the oxygenated mycolates cis- compounds were more inflammatory than trans- compounds (Fig. 1d). When the results obtained for cis- compounds are statistically compared, cis-methoxy-compound (KB52) induces higher TNF-α levels compared to cis-alpha TDM (MH175) or cis-keto TDM (AD132).

Synthetic AraMMs and GMMs Are Inflammatory

We next assessed the importance of the sugar moiety on the inflammatory potential of synthetic glycolipids. For that purpose, levels of pro-inflammatory cytokines produced by a cis-methoxy mycolate bound to trehalose (TDM-KB52 or TMM-KB51), or to glucose (GMM-SMP73) or arabinose (AraMM-MOD16) were evaluated. As shown in Figure 2a–d, significant TNF-α, IL-6, IL-12p40, and IL-1β levels were measured in BMDC culture supernatants with all the tested compounds after 24 h of incubation. At the highest concentration tested (1 μM), TDB induced significantly more IL-6, IL-1β, and IL-12p40 but higher TNF-α levels compared to cis-alpha TDM (MH175) or cis-keto TDM (AD132), whereas GMM-SMP73 – compared to TDB – induced comparable levels of IL-1β and TNF-α but less IL-12p40 and IL-6. Finally, TDM-KB52 induced similar levels of IL-6, IL-1β, and IL-12p40 but higher TNF-α levels as compared to levels achieved by TDB. Overall, these data indicate that AraMM-MOD16 is the weakest inducer of pro-inflammatory cytokines in comparison to TDM-KB52, TMM-KB51, and GMM-SMP73. In an additional experiment, we also compared the inflammatory potential of 5 synthetic GMMs and 3 AraMMs composed of mycolates from different classes and configuration (see online suppl. Fig. S2). Notably, all the tested GMMs induced TNF-α levels at least comparable to those obtained with TDB (see online suppl. Fig. S2). In contrast, the TNF-α levels induced with the 3 different synthetic AraMMs were lower than those induced with TDB or the tested GMMs. Thus, AraMMs are the weakest inducers of pro-inflammatory cytokines and TDMs the strongest inducers, while TMMs and GMMs induce responses comparable in magnitude to those observed after stimulation with TDB.

As a second read-out for the activation of BMDCs, we measured the surface expression of the costimulatory molecules CD86 and CD80, MHC-II molecules, and production of ROS induced by incubation with the synthetic glycolipids. Expression of CD86, CD80, and MHC-II was increased after 48 h of incubation with TDM-KB52, TMM-KB51, GMM-SMP73, AraMM-MOD16, and LPS and TDB controls as compared to non-stimulated BMDCs (Fig. 2e). AraMM-MOD16 (and LPS) stimulated CD86 expression to a lesser extent than the other mycolate esters. Expression of CD80 and MHC-II was increased by all 4 compounds to the same level as by TDB, TDM-KB52, TMM-KB51, and GMM-SMP73 all significantly induced the production of intracellular ROS, while the amount of TNF-α ± SD and data of 4 representative experiments have been pooled. Statistical analysis of results obtained for the TDM/TMM pairs was performed by the Mann-Whitney test. * p < 0.05, ** p < 0.01, and *** p < 0.001. 

Fig. 1. Synthetic TMM and TDM esters stimulate the in vitro production of TNF-α and IL-6 by BMDCs. a, b BMDCs derived from C57BL/6 mice were stimulated for 24 h in triplicate cultures with increasing concentrations of plate-coated synthetic cis-methoxy TMM-KB51, cis-methoxy TDM-KB52, or TDB. The supernatants were harvested from separate wells and the volume of pro-inflammatory cytokines (TNF-α and IL-6) was determined by sandwich ELISA. Results are expressed as the mean amount of cytokines ± SD of 3 independent experiments. c Separate BMDC cultures derived from C57BL/6 mice were stimulated for 24 h in triplicate with 9 pairs of synthetic TDM versus corresponding TMM esters at 0.1 μM, with evaporated ISO as a negative control and TDB or natural TDM at the same concentration as positive controls. The supernatants were harvested and the amount of TNF-α was determined by sandwich ELISA. Results are expressed as the mean ± SD and data of 3 representative experiments have been pooled. ** p < 0.01 and *** p < 0.001.
the weakest response was again observed for the synthetic AraMM tested (Fig. 2f).

**Synthetic AraMMs and GMMs Activate BMDCs by Mechanisms Dependent on the C-Type Lectin Receptor Mincle**

Several receptors have been reported to interact with mycolate esters. For example, recognition of natural arabinose mycolate esters has been described to be dependent on MyD88 and TLR-2 [22], while the C-type lectin receptor Mincle and MCL receptor have been associated with recognition of cord factor, its structural analogue TDB, TMM, and GMM from corynebacteria [18–21, 34]. In order to identify the signalling pathways involved in the inflammatory responses observed with the synthetic compounds, BMDCs were generated from C57BL/6 WT, Myd88–/–, Mincle–/–, FcRγ–/–, and MALT1–/– mice after stimulation with LPS 100 ng/mL, or TDB 10 μg/mL. Results are the mean ± SD and representative of at least 3 independent experiments. Statistical analysis on results obtained for synthetic compounds, TDB, or LPS compared to unstimulated cells was performed by the Mann-Whitney test: n.s., not significant.

In summary, these results indicate that synthetic GMMs and AraMMs activate BMDCs by mechanisms that are independent of the Myd88 pathway but dependent on the Mincle-FcRγ-Syk MALT1 pathway, demonstrating that the C-type lectin Mincle receptor can also recognise MAs from mycobacteria bound to glucose and arabinose.

**GMMs and AraMMs Activate the NLRP3 Inflammasome**

It was previously shown that the production of IL-1β induced by natural TDM (mix) and TDB is associated with activation of the NLRP3 inflammasome [23]. The inflammasome is a multiprotein platform which mediates the maturation of caspase-1. Mature caspase-1 cleaves pro-IL-1β and pro-IL-18, and induces the secretion of mature IL-1β and IL-18 [35]. The activation of the inflammasome by TDB is dependent on Mincle and has been shown to be essential for its ability to induce IL-17 responses [24]. As we found that synthetic GMMs and AraMMs also bind to Mincle and induce the production composed of the same cis-methoxy mycolate bound twice to trehalose (TDM-KB52) or once to trehalose (TMM-KB51), glucose (GMM-SMP73), arabinose (AraMM-MOD16), or controls (unstimulated, LPS 100 ng/mL, or TDB 10 μg/mL). Results are the mean ± SD and representative of at least 3 independent experiments. Statistical analysis on results obtained for synthetic compounds, TDB, or LPS compared to unstimulated cells was performed by the Mann-Whitney test: n.s., not significant. *p < 0.05. f BMDCs were treated for 30 min with 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) and stimulated for 4 h with 10 μg/mL of synthetic mycolate esters composed of the same cis-methoxy mycolate bound twice to trehalose (TDM-KB52) or once to trehalose (TMM-KB51), glucose (GMM-SMP73), arabinose (AraMM-MOD16), or controls (unstimulated, PMA 100 ng/mL, or TDB 10 μg/mL). The production of ROS by the tested compound (black line) was measured by flow cytometry and compared to unstimulated cells (grey shading).
of ROS species, we next analysed whether these compounds could also activate the inflammasome. A selected series of 4 mycolate esters composed of the same cis-methoxy mycolate were tested, i.e. TDM-KB52, TMM-KB51, GMM-SMP73, and AraMM-MOD16. BMDCs were primed with LPS 3 h prior to incubation for 5 h with the tested compounds and controls. As shown in Figure 4a, synthetic cis-methoxy TDM-KB52, TMM-KB51, GMM-SMP73, and AraMM-MOD16. BMDCs were primed with LPS 3 h prior to incubation for 5 h with the tested compounds and controls. As shown in Figure 4a, synthetic cis-methoxy TDM-KB52, TMM-KB51, GMM-SMP73, and AraMM-MOD16.
SMP73, and AraMM-MOD16 all stimulated IL-1β secretion by LPS-primed BMDCs to levels comparable to those achieved by natural TDM and TDB. Because the secretion of IL-1β is dependent on the maturation of caspase-1, we also analysed the secretion of the active caspase-1 p20 subunit in the supernatant and found that stimulation of LPS-primed BMDCs by TDM-KB52, TMM-KB51, GMM-SMP73, or AraMM-MOD16 was sufficient to induce caspase-1 maturation (Fig. 4b, c). Blocking of caspase activity with the pan-caspase-inhibitor Z-VAD-FMK strongly reduced the secretion of IL-1β (Fig. 4d), while, as expected, levels of secreted TNF-α were only marginally reduced following Z-VAD-FMK addition (Fig. 4e). Overall, these results indicate that synthetic TMM, GMM, and AraMM can also induce a caspase-1/inflammasome-dependent secretion of IL-1β in BMDCs. Using BMDCs derived from NLRP3−/− KO and caspase-1/11−/− mice, we observed that IL-1β induction by the tested compounds was completely abrogated in the absence of NLRP3 and significantly reduced in the absence of caspase-1/11−/− (Fig. 4f), demonstrating that synthetic TMM, GMM, and AraMM induce the production of IL-1β by NLRP3-dependent mechanisms (Fig. 4f). The fact that only levels of IL-1β but not of TNF-α were affected by the genetic deletion of NLRP3 or caspase-1/11 confirms that these deletions only impact inflammasome...
activation (Fig. 4g). As ROS production, potassium efflux, and cathepsin B activity are involved in inflamma-
some activation by TDB [23], we analysed whether simi-
lar mechanisms are also involved in BMDC activation by
synthetic mycolate esters. To this end, production of
IL-1β following incubation of BMDCs with ROS scaven-
ger (Ebselen) and synthetic TDM-KB52, TMM-KB51,
GMM-SMP73, and AraMM-MOD16 was measured. A
significant reduction in IL-1β secretion was observed (see
online suppl. Fig. S4A) following incubation with the dif-
ferent compounds in the presence of Ebselen. The inhibi-
tion of IL-1β secretion was also observed when Gliben-
clamide was used as an inhibitor of potassium efflux
pump or when a culture medium rich in potassium was
used to inhibit potassium efflux (see online suppl. Fig.
S4B). Finally, blocking cathepsin B activity with the phar-
macological inhibitor CA-074 and blocking actin poly-
merisation with cytochalasin D significantly reduced the
production of IL-1β by TDB and synthetic TDM-KB52,
TMM-KB51, GMM-SMP73, and AraMM-MOD16 my-
colate esters without affecting the level of IL-1β induced with the positive control ATP (see online suppl. Fig. S4C, D). In summary, these data indicate that ROS production, potassium efflux, cathepsin B activity, and phagocytosis are mechanisms involved in IL-1β induction by synthetic mycolate esters.

**Synthetic Mycolate Esters Demonstrate Inflammatory and Adjuvant Properties in vivo**

Our in vitro results indicated that synthetic TDMs and TMMs, GMMs, and to a lesser extent AraMMs had an inflammatory potential. To confirm these findings in vivo and to explore their possible use as novel adjuvants for subunit vaccines, w/o/w emulsions composed of IFA as a vehicle, synthetic mycolate esters, and ovalbumin as a test antigen were prepared and injected once in the 2 hind footpads of C57BL/6 mice. Footpad swelling was monitored for 1 week as a read-out of local inflammation; on day 7 we analysed the type of cells recruited in the footpad and the upregulation of proinflammatory chemokines and cytokines in these cells. Finally, OVA-specific immune responses were analysed by stimulating cells isolated from the lymph nodes draining the injection site 1 week after injection. Results obtained after injection of w/o/w emulsions composed of 30% IFA and cis-methoxy TDM-KB52, TMM-KB51, GMM-SMP73, or AraMM-MOD16 (10 μg/mouse) and ovalbumin (50 μg/mouse) are shown in Figures 5 and 6. Responses were compared with those obtained with a vehicle control (30% IFA + ovalbumin) or TDB w/o/w emulsions (30% IFA, TDB 10 μg/mouse and ovalbumin 50 μg/mouse). As shown in Figure 5a, neither AraMM-MOD16 nor 30% IFA vehicle control induced any footpad swelling, while TDM-KB52, TMM-KB51, and GMM-SMP73 induced a footpad swelling of 1–2 mm over 7 days, comparable to that observed for a w/o/w emulsion with TDB. Interestingly, GMM-SMP73 induced significantly weaker footpad swelling than TDB. Cells recruited to the site of injection were analysed by flow cytometry. The analysis of cells recruited to the footpad showed a high infiltration of granulocytes (Ly6C+ and Ly6G+) for TDB, natural TDM, TDM-KB52, TMM-KB51, and GMM-SPM73, but not for AraMM-MOD16 (Fig. 5b). qRT-PCR analysis confirmed that all the positive compounds (in terms of footpad swelling and granulocyte infiltration) also induced an increased expression of pro-inflammatory cytokines (IL-12p35, IL-1β, and TNF-α) and chemokines (CXCL1) as compared to vehicle control and AraMM-MOD16 (Fig. 5c–f). No significant difference was observed between TDB, natural TDM, TDM-KB52, TMM-KB51, and GMM-SMP73. The draining lymph node cell number increased 2-fold in animals injected with these 5 compounds, while the cell number was comparable in lymph nodes from animals injected with vehicle control or the AraMM-MOD16 group (Fig. 6a). Production of OVA-specific IL-2, IFN-γ, and IL-17A was measured in draining lymph node cell cultures stimulated in vitro with ovalbumin. Formulation with AraMM-MOD16 stimulated low levels of OVA-specific IL-2, IFN-γ, and no IL-17A production, whereas formulation with TDM-KB52, TMM-KB51, and GMM-SMP73 induced elevated levels of these cytokines, comparable to those achieved by TDB (Fig. 6b–d).

Our analysis of the in vitro inflammatory properties of the synthetic mycolate esters had shown that the class of mycolate bound to a given sugar exerted only a small influence on the magnitude of the inflammatory response (Fig. 1). Nevertheless, there was a trend of the tested synthetic methoxy TDM to induce more TNF-α than TDB or the alpha- and keto-compounds. We therefore compared the in vivo responses of w/o/w emulsions composed of cis-alpha TDM-MH175 or TMM-MH176 with responses obtained with w/o/w emulsions composed of cis-methoxy TDM-KB52 or TMM-KB51. No differences between the cis-alpha and cis-methoxy mycolate esters could be observed in terms of footpad swelling and OVA-specific IFN-γ and IL-17A responses (see online suppl. Fig. S5).

**Discussion**

The cell wall of mycobacteria is characterised by components that interact with different arms of the immune system in the case of infection. Several of these components have been associated with virulence and the capacity to modulate host immune responses. In this work, we were interested in analysing the role of esters of MAs using pure synthetic compounds. MAs are high molecular weight C-60 to C-90 2-alkyl-3-hydroxy fatty acids typical of mycobacteria. Different classes of MAs are present in mycobacteria, mainly alpha-, keto-, and methoxy-MAs, but also alkene and diene MAs. In addition, MAs can exist in different isomeric forms (e.g. cis- and trans-stereochemistry). In the mycobacterial cell wall, MAs are present as free MAs or esterified to different sugars (trehalose, glucose, or arabinose). TDM or cord factor is probably the most abundant and best studied of the non-cell wall-bound mycolate esters, and several studies have reported that changing the class of MA in TDM influences its inflammatory properties. Indeed, TDM from the Mtb ΔcmaA2 mutant, lacking trans-cyclopropanation of
Fig. 5. In vivo inflammatory properties of synthetic mycolate esters. C57BL/6 mice were injected subcutaneously in the 2 hind footpads with w/o/w emulsions composed of 30% IFA, 10 μg/mouse of specified synthetic mycolate esters, and 50 μg/mouse of ovalbumin. In the emulsion of the vehicle control group no glycolipid was present. In the TDB control group 10 μg/mouse of TDB replaced the synthetic glycolipid. a Mean footpad size (mm) of 5 mice tested individually was measured with a caliper on the day of injection and 1, 3, and 7 days after injection. b The percentage of granulocytes (Ly6G+ and Ly6C+) was determined in cells isolated from the footpad by flow cytometry 7 days after administration. c–f The relative expressions of cytokines and chemokines were determined by qRT-PCR in the footpad cells. Fold changes were determined in comparison to vehicle. Footpad swelling and the percentage of granulocytes induced by synthetic mycolate esters were statistically analysed in comparison to TDB using the Mann-Whitney test. n.s., not significant. * p < 0.05, ** p < 0.01, and *** p < 0.001.
MAs, is hyperinflammatory for macrophages compared to TDM extracted from wild-type Mtb [36]. Likewise, the cord factor isolated from Mtb ΔmmaA4, lacking oxygenated MA classes, induces in vitro more TNF-α and IL-12 in macrophages than TDM from wild-type Mtb [4]. On the other hand, TDM isolated from Mtb ΔpcaA (an enzyme required for α-mycolate cyclopropanation) is hypoinflammatory in macrophages [5]. In this study, we analysed the inflammatory power of 17 pure synthetic TDMs along with 13 TMMs, 5 GMMs, and 3 AraMMs.

Our results only partially confirm the data previously obtained using these mutant Mtb strains [4, 5, 36]. Indeed, the monoalkene TDM and particularly the dialkene TDM, respectively lacking 1 and 2 cyclopropanes, show a lower inflammatory potential, confirming the findings of Rao et al. [5]. However, we found that the class of mycolate (alpha- vs. keto- vs. methoxy-) and the cis- versus trans-conformation only poorly influences the intensity of the inflammatory responses induced by these compounds. Cis-methoxy-mycolate esters seem to be more...
inflammatory compared to cis-alpha- and cis-keto-mycolate esters in vitro, but this observation was not confirmed in vivo. It is important to mention that the naturally isolated TDM preparations from Mtb mutants were composed of a complex mixture containing diverse mycolates in terms of class and chain length (C-60 to C-90), while the synthetic compounds tested in our study were of a particular class and generally restricted in chain length from C-74 to C-84. Synthetic compounds with chain lengths varying in a wider range between C-60 and C-90 need to be tested to make definitive conclusions. Moreover, Ostrop et al. [37] have shown that natural TDM induces a different profile of pro-inflammatory cytokines and chemokines compared to TDB in primary human APCs. These results suggest a potential role of chain length or presence of chemical groups in the activation of primary human cells. To elucidate this, it would be of great interest to compare the inflammatory potential of the synthetic compounds of our study in primary human APCs.

In addition, with this study we were able to demonstrate that besides TDMs and TMMs, GMMs and AraMMs are also inflammatory mycolate esters. Their ability to induce inflammatory responses is linked to their interaction with the C-type lectin receptor Mincle. Using BMDCs of Mincle−/− mice and human reporter cells expressing murine Mincle, we showed that long-chain mycobacterial GMMs – similarly to corynebacterial GMMs – can indeed interact with Mincle [19]. These results are different from those previously reported by Ishikawa et al. [18], who showed that GMM isolated by trehalase treatment of natural TDM does not interact with mouse Mincle receptor. This difference in results is possibly linked to the use of products of enzymatic treatment as compared to the use of pure synthetic compounds in our study and in the study by van der Peet et al. [19]. In addition, Matsunaga et al. [38], reported that, shortly after infection, mycobacteria have a downregulated production of TDM and an upregulated production of GMM. This reciprocal regulation is caused by competitive substrate selection by antigen 85A. The results reported by Matsunaga et al. [38], coupled to the results of Ishikawa et al. [18], led to the hypothesis that upregulation of GMM production is an escape mechanism of pathogenic mycobacteria to avoid recognition by the innate immune system. Our results suggest that even in vivo a downregulation of TDM and an upregulation of GMM occur, innate immune cells remain able to recognise GMM via Mincle.

Regarding AraMMs, our results differ from what was described for natural AraMM purified from M. bovis BCG, for which a dependence on TLR-2/Myd88 was reported [22]. However, in the report by Miyauchi [22], arabino-mycolate esters obtained by acid hydrolysis of BCG cell wall skeleton were used, which consist of a complex mixture of mono-arabinose monomycolates, tetra-arabinose tetra-mycolates, penta-arabinose tetra-mycolates and hexa-arabinose tetra-mycolate. The relative proportion of these different compounds in the preparation was not quantified; we can therefore not exclude that mono-arabinose monomycolates signal via Mincle while the other arabinose mycolates would signal via TLR-2/MyD88. It is noteworthy that, to our knowledge, this is the first study demonstrating that the C-type receptor Mincle can recognise pentose-based glycolipids, even if the intensity of the induced downstream signal was lower than the signal induced by trehalose- and glucose-based glycolipids.

In addition, our study demonstrates that, like TDMs, TMMs, and GMMs, AraMMs also induce the activation of the NLRP3 inflammasome. It should be noted that, even if the tested synthetic AraMMs were not as inflammatory as the synthetic TDMs, TMMs, and GMMs in the in vitro and in vivo experiments performed, in an in vitro model involving an LPS priming of BMDCs, a level of IL-1β secretion was observed for all the tested AraMMs comparable to the levels observed for synthetic TDMs, TMMs, and GMMs. This indicates that synthetic AraMMs have a potential comparable to the other synthetic mycolate esters to induce NLRP3 inflammasome activation and, hence, pro-IL-1β processing. It is tempting to speculate that combining synthetic AraMM with a TLR-agonist could lead to the development of adjuvant formulations with Th1 and Th17 promoting potential. Indeed, the TLR agonist could trigger the production of pro-Th1 cytokines along with pro-IL-1β (similar to the LPS priming in our experimental set-up) and synthetic AraMM could lead to pro-IL-1β maturation by NLRP3 activation resulting in the induction of Th17 responses [24, 39].

The in vivo analysis of the tested synthetic mycolate esters in IFA formulations with ovalbumin confirmed the inflammatory properties of synthetic TDMs, TMMs, and GMMs as measured by footpad swelling following subcutaneous administration. No difference in terms of footpad swelling or OVA-specific T cell responses could be observed when comparing the cis-alpha TDM-MH175 or TMM-MH176 compounds to the cis-methoxy TDM-KB52 or TMM-KB51 compounds, indicating that also in vivo the class of mycolate does not influence the inflammatory power of mycolate esters. Interestingly, Huber et al. [40] recently reported that trehalose monoesters with
short acyl chains (C12, 14, 16, 18, 20) induce significantly lower Th1 and Th17 responses compared to trehalose diester analogues. These results demonstrated that the adjuvant property of simple fatty acids requires 2 acyl chains. In contrast to that study, we observed comparable levels of Th1 and Th17 immune responses between TDM-KB52 and TMM-KB51, or between TDM-MH175 and TMM-MH176, suggesting that, with a longer acyl chain, TMMs can also trigger strong immune responses in vivo. In contrast to what was reported by Shenderov et al. [39], purified peptidoglycan was not needed and formulation of these synthetic mycolate esters in IFA was sufficient in our hands to trigger antigen-specific Th17 responses along with Th1 responses. Differences in formulation and read-outs could account for this discrepancy. Our results indicate that synthetic TDMs, TMMs, and GMMs should be further evaluated as novel adjuvants for subunit vaccines to be used against infectious diseases for which Th1 and Th17 CD4+ T cell responses correlate with protection. However, it is known that natural TDM extracted from Mtb can be toxic in vivo [41]. Nevertheless, this toxicity is linked to the nature of the acyl chain bound to trehalose. Indeed, TDM from Rhodococcus sp. 4306 with a shorter chain length (C34–38) induces lower granulomatogenicity compared to TDM from Mtb [15]. In addition, using natural TDMs extracted from different mycobacteria species that vary in terms of the classes and proportions of mycolates present in their cell wall, Fujita et al. [42] showed that the classes of MA bound to trehalose can influence the toxicity of the molecule. Thus, toxicity of the synthetic compounds with an adjuvant potential described in this study should be assessed in vivo to down-select non-toxic compounds.

GMMs from mycobacteria are also protective non-protein antigens recognised by CD1b-restricted T cells. Hence, given this dual ability of GMMs to stimulate both innate and adaptive responses, it is tempting to speculate that administration of IFA formulations of synthetic GMMs with no additional adjuvant could stimulate protective immune responses. In future experiments it will be of interest to evaluate such formulations in animal models such as guinea pigs or human group 1 CD1 transgenic mice [43]. In addition, as already analysed for TMM [21] and in order to simplify the synthesis process, it would be interesting to determine the minimal carbon chain length necessary for the adjuvant potential of GMM and for its antigenic potential in tuberculosis vaccines. More importantly, this study raises the interesting possibility that GMM through Mincle and CD1b may contribute to both innate (induction of pro-inflammatory cytokines) and acquired (induction of Th1/Th17-CD1b-restricted T cell responses) immunity against mycobacteria. This fact provides an interesting possibility in the tuberculosis vaccine field to target both classical and non-classical T cell responses by combining synthetic GMM with a protective antigen.

Acknowledgements

Hermann Giresse Tima holds a FRIA PhD fellowship. This research was partially funded by the Interuniversity Attraction Pole Programme IAP 7/32 and by TBVAC2020 under grant agreement No. H2020-PHC-643381. MOM thanks the Ministry of Higher Education and Scientific Research, Kurdistan Region, Iraq, for the award of a PhD studentship. Roland Lang received support from the Deutsche Forschungsgemeinschaft (SFB 796/B6). We also thank Fabienne Jurion and Christophe van den Poel for technical support, and Virginie Maghe for advice concerning statistical analysis of the data.

References

1 Minnikin DE, Kremer L, Dover LG, Besra GS: The methyl-branched fortifications of Mycobacterium tuberculosis. Chem Biol 2002; 9: 545–553.
2 Verschoor JA, Baird MS, Grooten J: Towards understanding the functional diversity of cell wall mycolic acids of Mycobacterium tuberculosis. Prog Lipid Res 2012; 51:325–339.
3 Ojha AK, Baughn AD, Sambandan D, Hsu T, Trivelli X, Guerardel Y, et al: Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol 2008; 69:164–174.
4 Dao DN, Sweeney K, Hsu T, Gurcha SS, Nascimento IP, Roshevsky D, et al: Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production. PLoS Pathog 2008; 4:e100081.
5 Rao V, Fujitawa N, Porcelli SA, Glickman MS: Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J Exp Med 2005; 201:535–543.
6 Behling CA, Perez RL, Kidd MR, Staton GW, Hunter RL: Induction of pulmonary granulomas, macrophage procoagulant activity, and tumor necrosis factor-alpha by trehalose glycolipids. Ann Clin Lab Sci 1993; 23:256–266.
7 Perez RL, Roman J, Staton GW, Hunter RL: Extravascular coagulation and fibrinolysis in murine lung inflammation induced by the mycobacterial cord factor trehalose-6,6-dimycolate. Am J Respir Crit Care Med 1994; 149:510–518.
8 Yarkoni E, Rapp HJ: Granuloma formation in lungs of mice after intravenous administration of emulsified trehalose-6,6-dimycolate (cord factor): reaction intensity depends on size distribution of the oil droplets. Infect Immun 1977; 18:552–554.
18 Ishikawa E, Ishikawa T, Morita YS, Toyonaga
14 Barkan D, Hedhli D, Yan H-G, Huygen K,
17 Moody DB, Reinhold BB, Guy MR, Beckman
19 van der Peet PL, Gunawan C, Torigoe S, Ya-
16 Nishizawa M, Yamamoto H, Imagawa H, Bar-
11 Watanabe M, Aoyagi Y, Ridell M, Minnikin
180
9 Axelrod S, Oschkinat H, Enders J, Schlegel B,
12 Minnikin DE, Parlett JH, Magnusson M,
10 Gavin AL, Hoebe K, Duong B, Ota T, Martin
218:   664–673.
24 Desel C, Werninghaus K, Ritter M, Jozefows-
38 Al Dulayymi JR, Baird MS, Maza-Iglesias M,
23 Schweneker K, Gorka O, Schweneker M,
53 Mohammed M: Arabino-mycolates from
Hameed RT, Baols KS, Muzael M, et al: Syn-
25 Mohammed M, Jozefowski K, Zimmermann S, Hof-
37 Ostrop J, Jozefowski K, Zimmermann S, Hof-
41 Hunter RL, Armitige L, Jagannath C, Actor
42 Fujita Y, Okamoto Y, Uenishi Y, Sunagawa
33 Yarkoni E, Rapp HJ: Granuloma formation in
2009;   206:   2497–2509.
35 Schroder K, Tschopp J, Poeck H, Tschopp J, Peschel C, et al: The my-
28 Dietz CF, Werninghaus K, Ritter M, Jozefowski K, Zimmermann S, Hof-
218:   664–673.
24 Desel C, Werninghaus K, Ritter M, Jozefows-
23 Schweneker K, Gorka O, Schweneker M,
5722–5730.
38 Matsunaga I, Naka T, Talekar RS, McCon-
1938.
218:   664–673.
24 Desel C, Werninghaus K, Ritter M, Jozefowski K, Zimmermann S, Hof-
25 Mohammed M, Jozefowski K, Zimmermann S, Hof-
218:   664–673.
24 Desel C, Werninghaus K, Ritter M, Jozefowski K, Zimmermann S, Hof-
23 Schweneker K, Gorka O, Schweneker M,
25 Mohammed M, Jozefowski K, Zimmermann S, Hof-
11 Watanabe M, Aoyagi Y, Ridell M, Minnikin
180
9 Axelrod S, Oschkinat H, Enders J, Schlegel B,
12 Minnikin DE, Parlett JH, Magnusson M,
10 Gavin AL, Hoebe K, Duong B, Ota T, Martin
218:   664–673.
24 Desel C, Werninghaus K, Ritter M, Jozefowski K, Zimmermann S, Hof-
23 Schweneker K, Gorka O, Schweneker M,
25 Mohammed M, Jozefowski K, Zimmermann S, Hof-
11 Watanabe M, Aoyagi Y, Ridell M, Minnikin
180
9 Axelrod S, Oschkinat H, Enders J, Schlegel B,
12 Minnikin DE, Parlett JH, Magnusson M,
10 Gavin AL, Hoebe K, Duong B, Ota T, Martin
218:   664–673.
24 Desel C, Werninghaus K, Ritter M, Jozefowski K, Zimmermann S, Hof-
23 Schweneker K, Gorka O, Schweneker M,
25 Mohammed M, Jozefowski K, Zimmermann S, Hof-
11 Watanabe M, Aoyagi Y, Ridell M, Minnikin
180
9 Axelrod S, Oschkinat H, Enders J, Schlegel B,
12 Minnikin DE, Parlett JH, Magnusson M,
10 Gavin AL, Hoebe K, Duong B, Ota T, Martin
218:   664–673.
24 Desel C, Werninghaus K, Ritter M, Jozefowski K, Zimmermann S, Hof-
23 Schweneker K, Gorka O, Schweneker M,
25 Mohammed M, Jozefowski K, Zimmermann S, Hof-
11 Watanabe M, Aoyagi Y, Ridell M, Minnikin
180
9 Axelrod S, Oschkinat H, Enders J, Schlegel B,